By Maggie Fick LONDON, April 14 (Reuters) - Danish drugmaker Novo Nordisk, which has fallen behind Eli Lilly in the immensely ...

The race to develop the next generation of medicines just got faster. At least, that is the bet Novo Nordisk is making. The Danish pharmaceutical company announced a strategic partnership with OpenAI ...

Pharmaceutical giant Novo Nordisk is teaming with OpenAI to deploy artificial intelligence in an effort to speed up drug development. The Danish company said the collaborationwill pilot AI to analyze ...

Novo Nordisk said it would work with ChatGPT maker OpenAI on how to leverage artificial intelligence to discover new drugs, the latest AI partnership in the medical field as healthcare companies seek ...

OpenAI has announced a strategic partnership with pharma giant Novo Nordisk to use advanced AI for drug discovery, including analyzing complex datasets, identifying drug candidates and reducing the ...

Novo Nordisk is partnering with OpenAI to "bring new and better treatment options to patients faster," the Danish drugmaker said Tuesday. "Integrating AI in our everyday work gives us the ability to ...

Danish pharmaceutical company Novo Nordisk has partnered with OpenAI to support drug research and development. Through the partnership, Novo Nordisk said it plans to deploy advanced artificial ...

The drugmaker said it would integrate OpenAI’s models across its operations to help analyze complex datasets and reduce the time it takes to move from research to delivering treatments.